NASDAQ:VTGN

VistaGen Therapeutics Stock Forecast, Price & News

$2.21

+0.14 (+6.76 %)

(As of 01/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.03

Now: $2.21▼

$2.30

50-Day Range

$0.74

MA: $1.60▼

$2.40

52-Week Range

$0.30

Now: $2.21▼

$2.64

Volume1.65 million shs

Average Volume2.80 million shs

Market Capitalization$306.18 million

P/E RatioN/A

Dividend YieldN/A

Beta0.52

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines to treat diseases and disorders of the central nervous system. It focuses on depressive and social anxiety disorders. The company's lead product candidate is AV-101 that is in Phase II clinical trial for the treatment of chronic neuropathic pain, epilepsy, major depressive disorder (MDD), parkinson's disease levodopa-induced dyskinesia, and suicidal ideation; PH94B, a neuroactive nasal spray that is in Phase III clinical trial for social anxiety disorder (SAD), and Phase IIa clinical trial for generalized anxiety disorder; and PH10, a neuroactive nasal spray that is in Phase IIb clinical trial for MDD. It has licensing, sublicensing, and collaboration agreements with Pherin Pharmaceuticals, Inc.; BlueRock Therapeutics, LP; and Cato Research Ltd. The company also has a strategic licensing and collaboration agreement with EverInsight Therapeutics Inc. for the clinical development and commercialization of PH94B for multiple anxiety-related disorders in Greater China, South Korea, and Southeast Asia. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

MarketRank^™

Overall MarketRank^™

1.28 out of 5 stars

Medical Sector

715th out of 1,923 stocks

Pharmaceutical Preparations Industry

360th out of 773 stocks

3.5 Analyst's Opinion

Consensus Rating
VistaGen Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.50, VistaGen Therapeutics has a forecasted upside of 148.9% from its current price of $2.21.
Amount of Analyst Coverage
VistaGen Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
VistaGen Therapeutics has received 266 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
VistaGen Therapeutics has received 191 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
VistaGen Therapeutics has received 58.21% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about VistaGen Therapeutics and other stocks. Vote “Outperform” if you believe VTGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VTGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
VistaGen Therapeutics does not currently pay a dividend.
Dividend Growth
VistaGen Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, VistaGen Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 13.67% of the stock of VistaGen Therapeutics is held by insiders.
Percentage Held by Institutions
Only 3.13% of the stock of VistaGen Therapeutics is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for VistaGen Therapeutics are expected to decrease in the coming year, from ($0.26) to ($0.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of VistaGen Therapeutics is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of VistaGen Therapeutics is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:VTGN

Previous Symbol

CUSIPN/A

CIK1411685

Webwww.vistagen.com

Phone650-577-3600

Employees9

Debt

Debt-to-Equity RatioN/A

Current Ratio0.82

Quick Ratio0.82

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.12) per share

Price / Book-18.42

Profitability

EPS (Most Recent Fiscal Year)($0.50)

Net Income$-20,770,000.00

Net MarginsN/A

Return on EquityN/A

Return on Assets-272.12%

Miscellaneous

Outstanding Shares138,543,000

Market Cap$306.18 million

Next Earnings Date2/11/2021 (Estimated)

OptionableNot Optionable

$2.21

+0.14 (+6.76 %)

(As of 01/22/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive VTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.

VistaGen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions

How has VistaGen Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

VistaGen Therapeutics' stock was trading at $0.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VTGN stock has increased by 342.0% and is now trading at $2.21.
View which stocks have been most impacted by COVID-19.

Is VistaGen Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VistaGen Therapeutics stock.
View analyst ratings for VistaGen Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than VistaGen Therapeutics?

Wall Street analysts have given VistaGen Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but VistaGen Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is VistaGen Therapeutics' next earnings date?

VistaGen Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for VistaGen Therapeutics.

How were VistaGen Therapeutics' earnings last quarter?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.03. The firm had revenue of $0.33 million for the quarter, compared to analysts' expectations of $5 million.
View VistaGen Therapeutics' earnings history.

What price target have analysts set for VTGN?

3 Wall Street analysts have issued 12-month price targets for VistaGen Therapeutics' shares. Their forecasts range from $5.00 to $6.00. On average, they anticipate VistaGen Therapeutics' share price to reach $5.50 in the next year. This suggests a possible upside of 148.9% from the stock's current price.
View analysts' price targets for VistaGen Therapeutics or view Wall Street analyst' top-rated stocks.

Are investors shorting VistaGen Therapeutics?

VistaGen Therapeutics saw a drop in short interest during the month of December. As of December 31st, there was short interest totaling 2,340,000 shares, a drop of 18.5% from the December 15th total of 2,870,000 shares. Based on an average trading volume of 1,360,000 shares, the days-to-cover ratio is currently 1.7 days.
View VistaGen Therapeutics' Short Interest.

Who are some of VistaGen Therapeutics' key competitors?

Some companies that are related to VistaGen Therapeutics include Omeros (OMER), Northwest Biotherapeutics (NWBO), Arcutis Biotherapeutics (ARQT), Epizyme (EPZM), Theravance Biopharma (TBPH), Athenex (ATNX), BioXcel Therapeutics (BTAI), Phathom Pharmaceuticals (PHAT), Organogenesis (ORGO), Karyopharm Therapeutics (KPTI), Akero Therapeutics (AKRO), Zogenix (ZGNX), Proteostasis Therapeutics (PTI), Lexicon Pharmaceuticals (LXRX) and Annexon (ANNX).
View all of VTGN's competitors.

What other stocks do shareholders of VistaGen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas Corp. (LAC.TO) (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

Who are VistaGen Therapeutics' key executives?

VistaGen Therapeutics' management team includes the following people:

Mr. Shawn K. Singh, CEO & Director (Age 57, Pay $498k)
Dr. H. Ralph Snodgrass, Founder, Pres, Chief Scientific Officer & Director (Age 70, Pay $416.85k)
Mr. Jerrold D. Dotson CPA, CFO, VP & Sec. (Age 67, Pay $367.5k)
Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 54, Pay $300k)
Dr. Mark A. Smith, Chief Medical Officer (Age 65, Pay $416.85k)

What is VistaGen Therapeutics' stock symbol?

VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

How do I buy shares of VistaGen Therapeutics?

Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VistaGen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $2.21.

How big of a company is VistaGen Therapeutics?

VistaGen Therapeutics has a market capitalization of $306.18 million. The company earns $-20,770,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. VistaGen Therapeutics employs 9 workers across the globe.

What is VistaGen Therapeutics' official website?

The official website for VistaGen Therapeutics is www.vistagen.com.

How can I contact VistaGen Therapeutics?

VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here